BeiGene (HKG:6160, SHA:688235) granted options to three grantees to subscribe for an aggregate of 3,754 American Depositary Shares (ADSs) on Aug. 30, a Thursday bourse filing said.
The options, which were granted under a 2016 share option and incentive plan, are exercisable at $198.37 per ADS for a period of 10 years.
The company, on the same day, granted a total of 66,829 restricted share unit (RSUs) to 179 Grantees under the same scheme. The RSUs represent 868,777 underlying shares, representing around 0.06% of the company's total issued share capital.
Following the grant of the options and RSUs, the drug company will have 81,050,878 underlying shares available for future grants under the award plan.
Hong Kong-listed shares of the company closed nearly 3% higher on Thursday.
Price (HKD): $115.10, Change: $+2.9, Percent Change: +2.58%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。